JP2005510568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510568A5 JP2005510568A5 JP2003547416A JP2003547416A JP2005510568A5 JP 2005510568 A5 JP2005510568 A5 JP 2005510568A5 JP 2003547416 A JP2003547416 A JP 2003547416A JP 2003547416 A JP2003547416 A JP 2003547416A JP 2005510568 A5 JP2005510568 A5 JP 2005510568A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- disease
- disorder
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000003457 sulfones Chemical group 0.000 claims description 2
- 150000003462 sulfoxides Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 241000208125 Nicotiana Species 0.000 claims 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 4
- 206010057852 Nicotine dependence Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000025569 Tobacco Use disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020601 Hyperchlorhydria Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010061533 Myotonia Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047139 Vasoconstriction Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 2
- 229960003920 cocaine Drugs 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000002920 convulsive effect Effects 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 206010013932 dyslexia Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- -1 opioid Chemical compound 0.000 claims 2
- 230000001314 paroxysmal effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 235000019505 tobacco product Nutrition 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33450201P | 2001-11-30 | 2001-11-30 | |
| PCT/IB2002/004820 WO2003045967A1 (en) | 2001-11-30 | 2002-11-18 | Aryl fused azapolycyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510568A JP2005510568A (ja) | 2005-04-21 |
| JP2005510568A5 true JP2005510568A5 (enExample) | 2008-08-14 |
Family
ID=23307510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547416A Pending JP2005510568A (ja) | 2001-11-30 | 2002-11-18 | アリール基が結合したアザポリサイクリック化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6858624B2 (enExample) |
| EP (1) | EP1451202B1 (enExample) |
| JP (1) | JP2005510568A (enExample) |
| KR (1) | KR20040063939A (enExample) |
| CN (1) | CN1596263A (enExample) |
| AR (1) | AR037596A1 (enExample) |
| AT (1) | ATE405574T1 (enExample) |
| AU (1) | AU2002365314A1 (enExample) |
| BR (1) | BR0214578A (enExample) |
| CA (1) | CA2468717A1 (enExample) |
| CO (1) | CO5570673A2 (enExample) |
| DE (1) | DE60228478D1 (enExample) |
| DO (1) | DOP2002000518A (enExample) |
| ES (1) | ES2310626T3 (enExample) |
| GT (1) | GT200200243A (enExample) |
| HN (1) | HN2002000335A (enExample) |
| IL (1) | IL161836A0 (enExample) |
| NO (1) | NO20042214L (enExample) |
| PA (1) | PA8559201A1 (enExample) |
| PE (1) | PE20030724A1 (enExample) |
| PL (1) | PL369886A1 (enExample) |
| RU (1) | RU2004116320A (enExample) |
| TW (1) | TW200300346A (enExample) |
| UY (1) | UY27554A1 (enExample) |
| WO (1) | WO2003045967A1 (enExample) |
| ZA (1) | ZA200402994B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000038I1 (de) * | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| CA2511185C (en) | 2002-12-20 | 2012-09-18 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
| JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ | 改善された嗅ぎたばこ組成物 |
| US20090203658A1 (en) * | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| EP2198332A4 (en) * | 2007-09-06 | 2011-11-30 | 3M Innovative Properties Co | LIGHT CONDUCTOR WITH LIGHT EXTRACTION STRUCTURES FOR PROVIDING REGIONAL CONTROL OF LIGHT OUTPUT |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011030A1 (en) * | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
| EP0937077B1 (en) | 1996-10-30 | 2006-05-17 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| US6020335A (en) | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| DE122008000038I1 (de) | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| EP0955301A3 (en) | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| SK15952000A3 (sk) | 1998-04-29 | 2002-06-04 | Pfizer Products Inc. | Aryl-anelovaná azapolycyklická zlúčenina, jej použitie a farmaceutické kompozície na jej báze |
-
2002
- 2002-11-18 JP JP2003547416A patent/JP2005510568A/ja active Pending
- 2002-11-18 EP EP02803886A patent/EP1451202B1/en not_active Expired - Lifetime
- 2002-11-18 BR BR0214578-2A patent/BR0214578A/pt not_active IP Right Cessation
- 2002-11-18 WO PCT/IB2002/004820 patent/WO2003045967A1/en not_active Ceased
- 2002-11-18 KR KR10-2004-7008118A patent/KR20040063939A/ko not_active Abandoned
- 2002-11-18 AU AU2002365314A patent/AU2002365314A1/en not_active Abandoned
- 2002-11-18 RU RU2004116320/04A patent/RU2004116320A/ru not_active Application Discontinuation
- 2002-11-18 AT AT02803886T patent/ATE405574T1/de not_active IP Right Cessation
- 2002-11-18 DE DE60228478T patent/DE60228478D1/de not_active Expired - Fee Related
- 2002-11-18 IL IL16183602A patent/IL161836A0/xx unknown
- 2002-11-18 CA CA002468717A patent/CA2468717A1/en not_active Abandoned
- 2002-11-18 CN CNA028236289A patent/CN1596263A/zh active Pending
- 2002-11-18 PL PL02369886A patent/PL369886A1/xx not_active Application Discontinuation
- 2002-11-18 ES ES02803886T patent/ES2310626T3/es not_active Expired - Lifetime
- 2002-11-21 DO DO2002000518A patent/DOP2002000518A/es unknown
- 2002-11-25 TW TW091134186A patent/TW200300346A/zh unknown
- 2002-11-27 US US10/306,500 patent/US6858624B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000335A patent/HN2002000335A/es unknown
- 2002-11-27 GT GT200200243A patent/GT200200243A/es unknown
- 2002-11-28 AR ARP020104596A patent/AR037596A1/es unknown
- 2002-11-28 UY UY27554A patent/UY27554A1/es not_active Application Discontinuation
- 2002-11-28 PA PA20028559201A patent/PA8559201A1/es unknown
- 2002-11-28 PE PE2002001146A patent/PE20030724A1/es not_active Application Discontinuation
-
2004
- 2004-04-20 ZA ZA200402994A patent/ZA200402994B/en unknown
- 2004-04-26 CO CO04037673A patent/CO5570673A2/es not_active Application Discontinuation
- 2004-05-27 NO NO20042214A patent/NO20042214L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107089985B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 | |
| EP2774926B1 (en) | Morphinan derivative | |
| EP3350178B1 (en) | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors | |
| CN101684118B (zh) | 三环化合物作为甘氨酸转运抑制剂的用途 | |
| JP6851367B2 (ja) | Ｉｒａｋ４阻害剤、及びその応用 | |
| US20040235841A1 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
| HK1223104A1 (en) | Arginase inhibitors as therapeutics | |
| EP1799690B1 (de) | Thiazolyl-dihydro-indazole | |
| AU2014400628A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| KR101886945B1 (ko) | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 | |
| JP2005510568A5 (enExample) | ||
| RU2008138532A (ru) | Стандарты варениклина и контроль примесей | |
| US20190106451A1 (en) | Mannose-derived antagonists of fimh useful for treating disease | |
| US20230131535A1 (en) | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | |
| CA3090219A1 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| EP4384506A1 (en) | Process for polyamide synthesis | |
| EP2007774B1 (de) | Thiazolyldihydroindazol-derivate als proteinkinase- inhibitoren | |
| EP3057963B1 (en) | Piperazine derivatives and the use thereof as medicament | |
| EP3419979A1 (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| Bergeron et al. | Total synthesis of vibriobactin | |
| JP4322211B2 (ja) | ７−フェニルピラゾロピリジン化合物 | |
| RU2004116320A (ru) | Арилконденсированные азаполициклические соединения | |
| EP3592740B1 (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| CN104804001B (zh) | 4‑取代吡咯并[2,3‑d]嘧啶化合物及其用途 | |
| JP6814470B2 (ja) | モルヒナン誘導体 |